ArticleJournal of orthopaedic case reports2025
An Effectiveness and Tolerability of Tapentadol Nasal Spray in Low Back Pain.
Article in Journal of orthopaedic case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Low back pain (LBP) is one of the most prevalent musculoskeletal conditions, leading to significant disability and healthcare burden worldwide. Effective pain relief with minimal side effects is crucial for improving patient outcomes. Tapentadol, a dual-mechanism opioid with µ-opioid receptor agonism and norepinephrine reuptake inhibition, has shown potent analgesic effects. Intranasal administration is an emerging route that ensures rapid absorption and enhanced efficacy. However, limited real-world data exist on the clinical use of tapentadol nasal spray (NS) in LBP management. This study aimed to evaluate the effectiveness and tolerability of tapentadol NS in patients with LBP. Materials and Methods: This investigator-initiated, retrospective, real-world, observational study analyzed data from electronic medical records of adult LBP patients ≤65 years old treated with tapentadol NS for three consecutive days. The primary endpoint was change in score on the numeric pain rating scale (NPRS). The secondary endpoints were the proportion of patients requiring rescue medicine, change in global sleep quality score, and incidence of adverse events (AEs). Results: A total of 300 patients were included in the analysis. The mean ± standard deviation NPRS pain score decreased significantly from 7.00 ± 0.80 on day 0 to 1.38 ± 0.45 on day 3, reflecting an 80.29% reduction (P < 0.001 for all changes from baseline). Notably, 99.00% of patients achieved >51% pain reduction by day 3. Similar trends were observed across different age groups and between male and female patients. Only 1.67% (5/300) of patients required rescue medication (intravenous paracetamol). A significant improvement in sleep quality (P < 0.001) was also noted. Importantly, no AEs were reported, indicating excellent tolerability of tapentadol NS. Conclusion: Tapentadol NS demonstrated significant pain reduction and improvement in sleep quality in adult patients with LBP. The therapy was well tolerated, with no reported AEs and a minimal requirement for rescue medication. These findings suggest that tapentadol NS is an effective and safe treatment option for acute LBP. Future prospective studies with a longer follow-up period and a comparative analysis with other analgesic formulations are warranted to further establish its role in LBP management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.